HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by King, S. Search for Related Content PubMed Articles by King, S.

Short course nevirapine was better than zidovudine for reducing the risk of mother to child transmission of HIV-1 infection

Key Words: anti-HIV agents • disease transmission • HIV infections • HIV-1 • nevirapine • pregnancy complications • zidovudine

The first 150 words of the full text of this article appear below.

METHODS
Design: randomised controlled trial.

Allocation: {concealed}.^*

Blinding: {unblinded}.^*

Follow up period: 6–8 weeks, 14–16 weeks, and 18 months.

Setting: {Mulago hospital in Kampala, Uganda}.

Patients: 626 women who were {18 years of age (mean age 24.5 y) at >32 weeks gestation, tested HIV-1 positive, and lived near the study site. Exclusion criteria included current antiretroviral or HIV-1 immunotherapy, uncontrolled hypertension, haemoglobin concentration <75 g/l, blood creatinine concentration >1.5 mg/dl, blood alanine aminotransferase concentration >3 times the upper limit of normal, and chronic alcohol or illicit drug use.}

Interventions: Of the 313 mothers who were allocated to a 200 mg nevirapine tablet at the onset of labour, 308 gave birth to 308 firstborn neonates who received a single 2 mg/kg {calibrated oral syringe} dose of nevirapine suspension 72 hours after birth or at discharge from the hospital. Of the 313 mothers who were allocated to two 300 . . . [Full text of this article]

Susan King, MD

Hospital for Sick Children and University of Toronto
Toronto, Ontario, Canada